An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
- 16 July 2020
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 16 (8) , 723-734
Abstract
Phenytoin is a frequently used drug treatment for epilepsy. Genetic polymorphisms in the metabolism of phenytoin, particularly CYP2C9, are strongly associated with increased plasma concentrations a...Keywords
This publication has 120 references indexed in Scilit:
- Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspectiveAsia Pacific Allergy, 2013
- The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a Northern Han Chinese populationBMC Neurology, 2013
- PharmGKB summaryPharmacogenetics and Genomics, 2012
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Pharmacokinetics of Phenytoin: Reminders and DiscoveriesEpilepsy Currents, 2009
- Overview of Therapeutic Drug MonitoringThe Korean Journal of Internal Medicine, 2009
- Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA RecommendationsPharmacogenomics, 2008
- Idiosyncratic Adverse Reactions to Antiepileptic DrugsEpilepsia, 2007
- Current Understanding of Delayed Anticonvulsant Hypersensitivity ReactionsEpilepsy Currents, 2006
- Anticonvulsant Hypersensitivity SyndromeDrug Safety, 1999